(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of 24.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.02%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.95%.
Vir Biotechnology's revenue in 2026 is $65,495,000.On average, 11 Wall Street analysts forecast VIR's revenue for 2026 to be $41,979,162,848, with the lowest VIR revenue forecast at $31,735,241,948, and the highest VIR revenue forecast at $56,828,969,159. On average, 10 Wall Street analysts forecast VIR's revenue for 2027 to be $18,020,463,422, with the lowest VIR revenue forecast at $10,916,673,625, and the highest VIR revenue forecast at $27,394,140,137.
In 2028, VIR is forecast to generate $27,463,287,446 in revenue, with the lowest revenue forecast at $9,353,607,130 and the highest revenue forecast at $53,727,459,357.